Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / *W EXP 99/99/999
-
Number of holders
-
19
-
Total 13F shares, excl. options
-
2,231,947
-
Shares change
-
-48,941
-
Total reported value, excl. options
-
$1,359,753
-
Value change
-
+$51,692
-
Number of buys
-
3
-
Number of sells
-
7
-
Price
-
$0.001800
Institutional Holders of NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 (NAMSW) as of Q1 2023
As of 31 Mar 2023 NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 (NAMSW) had 19 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 2,231,947 shares of stock of the company.
Largest 10 holders included HIGHBRIDGE CAPITAL MANAGEMENT LLC, Frazier Life Sciences Management, L.P., RA CAPITAL MANAGEMENT, L.P., Ensign Peak Advisors, Inc, Bain Capital Life Sciences Investors, LLC, Exos TFP Holdings LLC, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Affinity Asset Advisors, LLC, Westchester Capital Management, LLC, and HRT FINANCIAL LP.
This table shows 18 institutional shareholders of the security as of 31 Mar 2023.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.